NCT03604419 - Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

214

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

July 23, 2019

Study Completion Date

July 23, 2019

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

PB-119 100 μg+ Glucophage®

Each patient will subsequently be randomized within the designated cohort to active drug or placebo

DRUG

PB-119 150 μg+ Glucophage®

Each patient will subsequently be randomized within the designated cohort to active drug or placebo

DRUG

PB-119 200 μg+ Glucophage®

Each patient will subsequently be randomized within the designated cohort to active drug or placebo

DRUG

PB-119 placebo + Glucophage®

Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Trial Locations (1)

Clinical Pharmacology of Miami, Miami